ClinicalTrials.govpublic full text
Defining the Ablative Dose for Y-90 TARE
hcc - hepatocellular carcinoma, margin, hcc, y90, liver cancer, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 834324
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.